Bioventus Inc. (BVS) key performance indicators and operating metrics (21 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Worldwide Revenue | 132.1M | FY2026-Q1 |
| Revenue from International | 15.6M | FY2026-Q1 |
| Revenue from Pain Treatments | 63.4M | FY2026-Q1 |
| Revenue from Restorative Therapies | 20.6M | FY2026-Q1 |
| Revenue from Surgical Solutions | 48M | FY2026-Q1 |
| Revenue from the United States | 116.4M | FY2026-Q1 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | 23.9M | FY2026-Q1 |
| Diluted Non-GAAP Earnings Per Share | 0.15 USD_per_share | FY2026-Q1 |
| Pain Treatments Revenue | 67.2M | FY2025-Q3 |
| Restorative Therapies Revenue | 21.3M | FY2025-Q3 |
| Surgical Solutions Revenue | 50.2M | FY2025-Q3 |
| Adjusted Net Income | 18M | FY2025-Q2 |
| Adjusted Operating Income | 31M | FY2025-Q2 |
| Adjusted EBITDA | 34M | FY2025-Q2 |
Back to BVS overview · BVS earnings · BVS holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.